BAY 1251152

Drug Profile

BAY 1251152

Alternative Names: BAY1251152

Latest Information Update: 23 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Jun 2016 Phase-I clinical trials in Haematological malignancies (Late-stage disease) in USA (IV) (NCT02745743)
  • 10 Feb 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater) in Spain (IV) (NCT02635672)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top